Publications

Publications

Filter Results: (247) Arrow Down

Show Results For

← Page 5 of 247 Results →
  • 02 Jan 2020
  • Op-Ed

Medicare for All or Public Option: Can Either Heal Health Care?

for All published by the Harvard Business Review. [Image: Hispanolistic] Related Reading Germany May Have the Answer for Reducing Drug Prices What Hospitals Must Learn to Compete Making Health Insurance That... View Details
Keywords: by Regina E. Herzlinger and James Wallace; Health; Public Administration
  • 28 Jul 2015
  • First Look

First Look: July 28, 2015

come up with an innovative drug for Hepatitis C, which affected 180 million people worldwide. The drug was priced at $1,000 a pill for the U.S. market. Gilead had to decide how... View Details
Keywords: Carmen Nobel
  • 04 Feb 2014
  • First Look

First Look: February 4

products at reasonable prices and runs a highly popular advertising campaign that spoofs current events. It offers its farmers 80% of the consumer's dollar for milk, compared with 35% to 40% typical in some Western markets. Amul's... View Details
Keywords: Sean Silverthlorne
  • 2023
  • Article

Dynamic HTA for Digital Health Solutions: Opportunities and Challenges for Patient-Centered Evaluation

By: Jan B. Brönneke, Annika Herr, Simon Reif and Ariel D. Stern
Germany’s 2019 Digital Healthcare Act (Digitale-Versorgung-Gesetz, or DVG) created a number of opportunities for the digital transformation of the health care delivery system. Key among these was the creation of a reimbursement pathway for patient-centered digital... View Details
Keywords: Digital Transformation; Applications and Software; Product Development; Insurance; Policy; Health Industry; Germany
Related
  • 20 Nov 2007
  • First Look

First Look: November 20, 2007

  Working PapersNone this week   PublicationsFinancial Development, Bank Ownership, and Growth. Or, Does Quantity Imply Quality? Author:Shawn Cole Periodical:Review of Economics and Statistics (forthcoming) Abstract In 1980, India nationalized its large private banks.... View Details
Keywords: Martha Lagace
  • March 2008
  • Case

Novartis AG: Science-Based Business

By: H. Kent Bowen and Courtney Purrington
Novartis is a science-based drug company, which has important implications for its business strategy. It is one of the largest pharmaceutical companies in the world with over $38B in sales in 2007. Pharmaceuticals account for slightly over $24B of that total. In 2007,... View Details
Keywords: Innovation and Invention; Resource Allocation; Product Development; Partners and Partnerships; Research and Development; Science-Based Business; Pharmaceutical Industry
Related
  • September 2024
  • Case

Google Quantum AI

By: David B. Yoffie, Michael A. Cusumano and Matt Higgins
Quantum computing may be the most important nascent computing technology of the 21st century. It has the potential to impact industries ranging from drug discovery to cybersecurity. Google's Quantum AI is one of the leaders in quantum research. This case explores the... View Details
Keywords: Business Model; Price; Technological Innovation; Resource Allocation; Business Strategy; Information Technology Industry
Related
  • June 2024
  • Article

Valuing the Societal Impact of Medicines and Other Health Technologies: A User Guide to Current Best Practices

By: Jason Shafrin, Jaehong Kim, Joshua T. Cohen, Louis P. Garrison, Dana A. Goldman, Jalpa A. Doshi, Joshua Krieger, Darius N. Lakdawalla, Peter J. Neumann, Charles E. Phelps, Melanie D. Whittington and Richard Willke
This study argues that value assessment conducted from a societal perspective should rely on the Generalized Cost-Effectiveness Analysis (GCEA) framework proposed herein. Recently developed value assessment inventories—such as the Second Panel on Cost-Effectiveness’s... View Details
Keywords: Health Care and Treatment; Valuation; Cost vs Benefits; Society
Related
  • 14 Nov 2017
  • First Look

New Research and Ideas: November 14, 2017

Publisher's link: https://www.hbs.edu/faculty/Pages/item.aspx?num=53507 forthcoming Journal of Financial Economics Bubbles for Fama By: Greenwood, Robin, Andrei Shleifer, and Yang You Abstract—We evaluate Eugene Fama's claim that stock View Details
Keywords: Carmen Nobel
  • Web

Overview | MBA

uncertainties in affecting these opportunities. Develop approaches to ethical dilemmas bedeviling novel therapeutics, including investment in neglected diseases, the provision of life-saving drugs to disadvantaged patients and those in... View Details
  • 16 Jul 2008
  • Op-Ed

What Should Employers Do about Health Care?

frequently in search of a better deal, which has meant that their employees needed to switch as well. They have tried to pare back covered services, thrown up barriers to expensive drugs and treatments, and recently, begun to pass more... View Details
Keywords: by Michael E. Porter, Elizabeth O. Teisberg & Scott Wallace; Health
  • 14 Jul 2006
  • Op-Ed

The Case for Consumer-Driven Medicaid

The Medicaid program provides a much needed health insurance safety net for 52 million of our nation's poor and medically needy, but its price tag threatens the financial stability of the states, growing 9.5 percent in 2004 alone—far in... View Details
Keywords: by Regina E. Herzlinger
  • Web

Faculty & Advisors | MBA

Underscore VC, she invested in fast growing B2B software startups, including life sciences tech products used by leading biopharma companies across the drug development cycle from R&D to commercial stages. She began her career at Michael... View Details
  • 05 Sep 2023
  • Book

Failing Well: How Your ‘Intelligent Failure’ Unlocks Your Full Potential

In the 1990s, after drugmaker Eli Lilly spent more than a decade and millions of dollars developing the new drug Alimta to treat lung cancer, the medication came up short in effectively treating cancer in expanded trials. While the... View Details
Keywords: by Michael Blanding
  • Research Summary

Regulatory Change/Business-Government Relations

“Sources of Learning Heterogeneity: Discontinuous Regulatory Shock and its Impact on Organizational Search Behaviors”

Co-authoring with Jerry Kim, in this study I look at how discontinuous regulatory shock shapes organizational... View Details

Keywords: Business ＆ Government Relations; Regulations; Regulatory Capture; Pharmaceutical Industry; United States
  • 10 Oct 2007
  • First Look

First Look: First Look: October 10

defeated by a less reformist coalition. Stock prices of government-controlled companies that had been slated for definite privatization by the BJP dropped by 3.5 percent relative to private firms. Surprisingly, government-controlled... View Details
Keywords: Martha Lagace
  • Web

Great American Business Leaders of the 20th Century - Leadership

William H. Danforth Ralston Purina Company, 1894–1932 Justin Dart United Drug Company, 1943–1980 Francis B. Davis Jr. United States Rubber Company, 1929–1942 Arthur V. Davis Alcoa, 1910–1928 Charles S. Davis Borg-Warner Corporation,... View Details
  • 05 Dec 2017
  • First Look

First Look at New Research and Ideas, December 5, 2017

conformity comes at a steep price for our careers and personal lives. When we mindlessly accept rules and norms rather than questioning and constructively rebelling against them, we ultimately end up stuck and unfulfilled. As leaders, we... View Details
Keywords: Sean Silverthorne
  • 30 Jun 2022
  • HBS Case

Peloton Changed the Exercise Game. Can the Company Push Through the Pain?

demand, which led to shipment delays, followed by pricing confusion and a series of public relations bungles—just as the pandemic eased and people began returning to gyms. Peloton scrambled by recalling items and dropping prices, amid an... View Details
Keywords: by Lane Lambert; Media & Broadcasting; Health; Bicycle
  • 12 Feb 2008
  • First Look

First Look: February 12, 2007

Moskowitz, and Annette Vissing-Jørgensen Abstract We provide new evidence on the success of long-run risks in asset pricing by focusing on the risks borne by stockholders. Exploiting micro-level household consumption data, we show that... View Details
Keywords: Martha Lagace